MBX Biosciences falls 3.4% on wider loss despite earnings beat
Clinical-stage biotech reports strong pipeline progress but R&D spending drives net loss to $87M
MBX Biosciences shares fell 3.4% on Thursday despite the clinical-stage biotechnology company beating quarterly earnings expectations, as investors focused on widening losses driven by increased research and development spending.
The Carmel, Indiana-based company reported an adjusted loss per share of $0.49 for the fourth quarter of 2025, beating analyst estimates of $0.66 by $0.17, according to data from FXEmpire. However, the stock declined to $27.95 as the company's net loss widened 40% year-over-year to $87.0 million, reflecting substantial investments in its clinical pipeline.
Research and development expenses reached $79.2 million for the full year 2025, up from $57.4 million in the prior year, according to company filings. The increased spending was primarily attributed to ongoing Phase 1 clinical trials for MBX 4291, Phase 2 trials for canvuparatide, and preparatory activities for canvuparatide's Phase 3 trial.
Despite the financial pressure, the company's clinical pipeline continues to advance. MBX successfully completed an End-of-Phase 2 meeting with the FDA for its hypoparathyroidism treatment, canvuparatide, establishing a clear path forward for a pivotal Phase 3 trial scheduled to begin in the third quarter of 2026. The program has also received Orphan Drug Designation from the European Medicines Agency.
"We view 2026 as a data-rich period for MBX," analysts at Truist Securities wrote, reiterating a Buy rating with a $50 price target. The firm expects key readouts in the second quarter of 2026, including one-year open-label extension data for canvuparatide and proof-of-concept data from imapextide's Phase 2 trial in postbariatric hypoglycemia.
The company's financial position remains robust for a clinical-stage biotech. MBX reported $459.1 million in pro forma cash and investments as of December 31, 2025, which management expects will fund operations into 2029, according to a company press release.
Analyst sentiment remains broadly positive despite Thursday's decline. The stock carries a consensus target price of $61.20, with 10 of 11 analysts rating it a Buy or Strong Buy, according to market data. This represents significant upside potential from current levels, assuming clinical trials continue to progress as planned.
MBX's pipeline focuses on precision endocrine peptide (PEP) therapies designed to overcome the limitations of natural peptides. Beyond canvuparatide for hypoparathyroidism, the company is developing imapextide (MBX 1416) for postbariatric hypoglycemia, which completed Phase 1 trials and demonstrated a median half-life of approximately 90 hours, supporting once-weekly dosing, according to clinical trial data.
The stock's performance reflects broader tensions in the biotechnology sector, where investors weigh clinical progress against burn rates and the long path to commercialization. MBX's market capitalization grew nearly 130% during 2025, reaching approximately $1.4 billion by December, though shares have declined about 16% over the past 30 days, according to Public.com data.
Looking ahead, investors will focus on the second quarter 2026 data readouts that Truist highlighted, as well as the initiation of the Phase 3 canvuparatide trial in the third quarter. These milestones will be critical for validating the company's precision peptide platform and determining whether the current valuation levels are justified.